The HR+ type breast cancer accounts for nearly 70 per cent of all cases in India. (File Photo) An Indian team of researchers has identified a key genetic reason why patients with the most common type of breast cancer in India become resistant to standard hormone therapies used for treatment. Researchers from University of Delhi , South Campus, and Tata Memorial Hospital, Mumbai , have found that loss or damage to a gene called CDKN1B could be one of the reasons why standard drugs used to treat what is known as hormone receptor–positive (HR+) breast cancer do not work effectively in some patients. The HR+ type breast cancer accounts for nearly 70 per cent of all cases in India, and is treated with routine hormonal therapy using drugs like tamoxifen that block or reduce the effect of hormones like estrogen which drive the growth of breast cancer cells.…